SLC5A2 and type 2 diabetes mellitus: Further emerging evidence, albeit from a much smaller trial, has linked treatment with other SGLT2 inhibitors to reductions in liver fat (and ALT) equivalent to those seen with pioglitazone in individuals with type 2 diabetes [30].